Codexis Reports Fourth Quarter and Fiscal Year 2023 Financia

28.02.2024 - Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End ...

Related Keywords

United States , John Maraganore , David Butler , Lauren Musto , Carrie Mckim , Masad Damha , Jim Lalonde , Codexis Inc , Synthesis Innovation Lab , Innovatus Capital Partners , James Mcgill Professor At University , Securities Exchange , Exchange Commission , Health Science , Pfizer , Nasdaq , Alnylam Pharmaceuticals , Hongene Biotech Corporation , Securing Early Access Customers , Manufacturing Platform , Codex Hicap , Pharmaceutical Manufacturing , Stephen Dilly , Chief Executive Officer , Innovation Lab , Recent Business , Enzyme Catalyzed Oligonucleotide , Strategic Advisory Board , Distinguished James , Mcgill Professor , Mcgill University , Senior Vice President , Chief Technology Officer , Investor Relations , Codexi Codex Hicap , San Carlos , Securities Act , Securities Exchange Act , Codexi Annual Report , Consolidated Statements , Except Per Share Amounts , Months Ended December , Ended December ,